MARTELLUCCI, IGNAZIO
MARTELLUCCI, IGNAZIO
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
2010-01-01 Correale, P; Remondo, C; Carbone, Sf; Ricci, V; Migali, C; Martellucci, I; Licchetta, A; Addeo, R; Volterrani, L; Gotti, G; Rotundo, Ms; Tassone, P; Sperlongano, P; Abbruzzese, A; Caraglia, M; Tagliaferri, P; Francini, G
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy
2018-01-01 Petrioli, Roberto; Chirra, Martina; Messuti, Luciana; Fiaschi, Anna Ida; Savelli, Vinno; Martellucci, Ignazio; Francini, Edoardo
First-line pharmacotherapies and survival among patients diagnosed with non-resectable NSCLC: A real-life setting study with gender prospective
2021-01-01 Spini, A.; Gini, R.; Rosellini, P.; Singier, A.; Bellan, C.; Pascucci, A.; Leoncini, L.; Mathieu, C.; Martellucci, I.; Furiesi, F.; Giorgi, S.; Donnini, S.; Roberto, G.; Ziche, M.; Salvo, F.
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.
2013-01-01 Botta, C.; Barbieri, V.; Ciliberto, D.; Rossi, A.; Rocco, D.; Addeo, R.; Staropoli, N.; Pastina, Pierpaolo; Marvaso, G.; Martellucci, Ignazio; Guglielmo, A.; Pirtoli, Luigi; Sperlongano, P.; Gridelli, C.; Caraglia, M.; Tassone, P.; Tagliaferri, P.; Correale, P.
Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients
2020-01-01 Palmieri, M.; Baldassarri, M.; Fava, F.; Fabbiani, A.; Gelli, E.; Tita, R.; Torre, P.; Petrioli, R.; Hadijstilianou, T.; Galimberti, D.; Cinotti, E.; Bengala, C.; Mandala, M.; Piu, P.; Miano, S. T.; Martellucci, I.; Vannini, A.; Pinto, A. M.; Mencarelli, M. A.; Marsili, S.; Renieri, A.; Frullanti, E.
| Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
|---|---|---|---|---|
| Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients. | 1-gen-2010 | Correale, P; Remondo, C; Carbone, Sf; Ricci, V; Migali, C; Martellucci, I; Licchetta, A; Addeo, R; Volterrani, L; Gotti, G; Rotundo, Ms; Tassone, P; Sperlongano, P; Abbruzzese, A; Caraglia, M; Tagliaferri, P; Francini, G | - | |
| Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy | 1-gen-2018 | Petrioli, Roberto; Chirra, Martina; Messuti, Luciana; Fiaschi, Anna Ida; Savelli, Vinno; Martellucci, Ignazio; Francini, Edoardo | - | |
| First-line pharmacotherapies and survival among patients diagnosed with non-resectable NSCLC: A real-life setting study with gender prospective | 1-gen-2021 | Spini, A.; Gini, R.; Rosellini, P.; Singier, A.; Bellan, C.; Pascucci, A.; Leoncini, L.; Mathieu, C.; Martellucci, I.; Furiesi, F.; Giorgi, S.; Donnini, S.; Roberto, G.; Ziche, M.; Salvo, F. | - | |
| Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. | 1-gen-2013 | Botta, C.; Barbieri, V.; Ciliberto, D.; Rossi, A.; Rocco, D.; Addeo, R.; Staropoli, N.; Pastina, Pierpaolo; Marvaso, G.; Martellucci, Ignazio; Guglielmo, A.; Pirtoli, Luigi; Sperlongano, P.; Gridelli, C.; Caraglia, M.; Tassone, P.; Tagliaferri, P.; Correale, P. | - | |
| Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients | 1-gen-2020 | Palmieri, M.; Baldassarri, M.; Fava, F.; Fabbiani, A.; Gelli, E.; Tita, R.; Torre, P.; Petrioli, R.; Hadijstilianou, T.; Galimberti, D.; Cinotti, E.; Bengala, C.; Mandala, M.; Piu, P.; Miano, S. T.; Martellucci, I.; Vannini, A.; Pinto, A. M.; Mencarelli, M. A.; Marsili, S.; Renieri, A.; Frullanti, E. | - |